| 孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果 |
| |
| 引用本文： | 韦春峥,莫 彬,莫善圆,黄 涛.孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果[J].医学信息,2019,0(20):142-144. |
| |
| 作者姓名： | 韦春峥 莫 彬 莫善圆 黄 涛 |
| |
| 作者单位： | （河池市第三人民医院儿科，广西 河池 547000） |
| |
| 摘 要： | 目的 观察布地奈德联合孟鲁司特钠对儿童支气管哮喘合并变应性鼻炎的临床疗效及对炎性反应指标的影响，为进一步提高其治疗效果提供参考。方法 选择2018年1月~12月我院收治的106例支气管哮喘合并变应性鼻炎患儿，随机分为对照组和观察组，各53例。对照组给予布地奈德治疗，观察组在对照组的基础上联合孟鲁司特钠治疗，比较两组治疗前后哮喘症状评分、过敏性鼻炎症状评分、血清白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平。结果 对照组哮喘症状评分为（6.59±2.21）分，高于观察组的（4.92±1.95）分，差异有统计学意义（P＜0.05）；对照组过敏性鼻炎症状评分为（4.20±1.37）分，高于观察组的（3.52±1.26）分，差异有统计学意义（P＜0.05）；对照组血清IL-6水平为（109.48±26.37）ng/L，高于观察组的（93.79±23.62）ng/L，差异有统计学意义（P＜0.05）；对照组血清TNF-α水平为（351.39±46.37）ng/L，高于观察组的（313.50±37.15） ng/L，差异有统计学意义（P＜0.05）。结论 孟鲁司特钠联合布地奈德可有效改善支气管哮喘合并变应性鼻炎儿童的临床症状及炎性反应指标，具有良好临床效果。
|
| 关 键 词： | 孟鲁司特钠 布地奈德 儿童 支气管哮喘 变应性鼻炎 |
Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis |
| |
| WEI Chun-zheng,MO Bin,MO Shan-yuan,HUANG Tao.Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis[J].Medical Information,2019,0(20):142-144. |
| |
| Authors: | WEI Chun-zheng MO Bin MO Shan-yuan HUANG Tao |
| |
| Affiliation: | (Department of Pediatrics,the Third People's Hospital of Hechi,Hechi 547000,Guangxi,China) |
| |
| Abstract: | Objective To observe the clinical efficacy of budesonide combined with montelukast sodium in children with bronchial asthma complicated with allergic rhinitis and its influence on inflammatory response index, and provide reference for further improving its therapeutic effect. Methods 106 children with bronchial asthma complicated with allergic rhinitis were enrolled in our hospital from January to December 2018. They were randomly divided into control group and observation group, with 53 cases in each group. The control group was treated with budesonide. The observation group was treated with montelukast sodium on the basis of the control group. The asthma symptom score, allergic rhinitis symptom score, serum interleukin-6 (IL-6) were compared before and after treatment. And tumor necrosis factor-α (TNF-α) levels. Results The asthma symptom score of the control group was (6.59±2.21), which was higher than that of the observation group (4.92±1.95),the difference was statistically significant (P<0.05). The score of allergic rhinitis symptoms in the control group was (4.20±1.37). Compared with the observation group (3.52±1.26), the difference was statistically significant (P<0.05); the serum IL-6 level of the control group was (109.48±26.37) ng/L, which was higher than that of the observation group (93.79±23.62)ng/L, the difference was statistically significant (P<0.05); the serum TNF-α level in the control group was (351.39±46.37) ng/L, which was higher than that of the observation group (313.50±37.15) ng/L,the difference was statistically significant (P<0.05). Conclusion Montelukast sodium combined with budesonide can effectively improve the clinical symptoms and inflammatory response of children with bronchial asthma complicated with allergic rhinitis, and has good clinical results. |
| |
| Keywords: | Montelukast sodium Budesonide Children Bronchial asthma Allergic rhinitis |
|
| 点击此处可从《医学信息》浏览原始摘要信息 |
|
点击此处可从《医学信息》下载全文 |
|
